Search PubMed⌕ Search

Biomedical subjects

G Bertelli

Publications and source records attributed to G Bertelli.

At least 73 records · Page 4Linked to original sources
PubMed1987

Opioid peptides. Biological study of [D-MetO2] dermorphin analogues in relation to the plurality of opioid receptors. XI.

The opioid activity pattern of 8 dermorphin tetrapeptides, W-Tyr-D-MetO-Phe-Xaa-Y (W = H, H2N-C = (NH); Xaa = Gly, 2-aminoethanol, sarcosine; Y = NH2, NH-alkyl), was determined in guinea-pig ileum (GPI) preparations and in brain binding assays and compared with their antinociceptive potency in mice. Almost all modifications increased potency on the GPI test as well as the antinociceptive action of the parent H-Tyr-D-Ala-Phe-Gly-NH2. Dermorphin, H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, and related tetrapeptide analogues show negligible K-binding activity and, like morphine, possess a higher affinity to mu- than delta-receptors. Nevertheless the correlation of analgesia with the effects on GPI and binding data separate the peptides from morphine. For example, in comparison with the opiate alkaloid H-Tyr-D-MetO-Phe-Gly-ol and H-Tyr-D-MetO-Phe-Gly-NH2 displayed a lower affinity for mu sites, a moderately higher potency on GPI but an exceptionally stronger analgesia, being respectively 350 and 1500 times as potent an analgesic as morphine. This may involve different subpopulations of opioid mu-receptors.

Animals↗
PubMed1987

Metastatic breast cancer: an analysis of prognostic factors in patients treated with aminoglutethimide.

An analysis of 127 women with metastatic breast cancer was carried out. All patients were treated with aminoglutethimide: of 117 evaluable patients, 29 responded, 46 remained stable and 42 progressed. A series of patients' characteristics were analyzed for their prognostic importance for response to this drug. The most important features able to predict response were found to be a previous response to tamoxifen and a long disease-free survival after mastectomy.

Adult↗
PubMedDate not supplied

Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients.

Chemotherapy is a major tool for metastatic breast cancer treatment. In this study, a series of 316 patients have been analyzed to evaluate the time needed to reach tumor response by means of combination chemotherapy. Twenty-five percent of patients responded within 3 months and virtually all responses occurred within 7.5 months. The time curves of response (any) and best response are superimposable. A subset analysis has shown that the following pretreatment characteristics predict a significantly longer time to response: prior exposure to adjuvant chemotherapy, nodal positivity at diagnosis, no previous endocrine treatment and osseous metastases.

Age Factors↗
PubMedDate not supplied

Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer.

Twenty-four outpatients with locally advanced (inoperable or unsuitable for radical radiotherapy) or metastatic non-small-cell lung cancer were treated with carboplatin (300 mg/m2 day 1)+etoposide (120 mg/2 day 1-3), every 3 weeks. Two patients died of disease progression before completing at least 2 cycles of chemotherapy. Four patients (16.7%) obtained a partial response, 10 had disease stabilization (41.7%) and 8 progressed (33.3%). Median overall survival was 8 months (range 1-22). Toxicity was moderate, with no nephro-, neuro- or ototoxicity.

Aged↗
PubMedDate not supplied

Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.

BACKGROUND: Toremifene is a new antiestrogen, which in nonclinical studies appears less carcinogenic than tamoxifen. Clinical trials of adjuvant toremifene vs. tamoxifen in breast cancer patients are ongoing. This study aimed to evaluate the short-term effects of changing from adjuvant tamoxifen to toremifene. PATIENTS AND METHODS: Twenty postmenopausal breast cancer patients receiving adjuvant tamoxifen, 20 mg/day, were switched to toremifene 60 mg/day. The effects on the uterus were evaluated prospectively by transvaginal ultrasound; tolerability was assessed clinically. RESULTS: In 14 patients who had uterine abnormalities (endometrial thickening or polyps) under tamoxifen, no significant changes occurred during a median of 18 months (range 7-24) of toremifene treatment. Out of six patients who had entered the study due to intolerance to tamoxifen, however, 3 tolerated toremifene well. CONCLUSION: Toremifene does not modify previous uterine changes induced by tamoxifen. For some patients who do not tolerate tamoxifen, however, switching to toremifene may allow the continuation of adjuvant antiestrogenic therapy.

Aged↗
PubMedDate not supplied

Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.

Since most patients with breast cancer are treated with CMF as first line chemotherapy (usually in the adjuvant setting), schedules with alternative drugs are needed for the metastatic disease. In this study a new combination of Mitomycin, Epidoxorubicin and Vinblastine was employed in a group of 24 patients with metastatic breast cancer. A response rate of 37.5% was observed with a mild to moderate toxicity.

Antineoplastic Combined Chemotherapy Protocols↗
PubMedDate not supplied

Continuous venous infusion of vindesine in metastatic breast cancer: experience with a subcutaneously implanted system and portable pump.

Fourteen patients with advanced pretreated breast cancer were treated with vindesine in continuous venous infusion (1.5 mg/sm/24 hours for 72 hours every 3 weeks). A totally implanted venous access and a portable pump were used. A total of 33 courses was administered. No objective response was observed and treatment was stopped. Drug-related toxicity consisted mainly of alopecia (64% of patients), nausea and vomiting (29%) and mucositis (29%). Catheter - related toxicity was observed in 6 patients (43%) and consisted of infection of the skin pocket in 4 patients and dislodging of the needle and catheter break in one patient. The feasibility of continuous venous infusion of vesicant drugs in outpatients is discussed.

Adult↗
PubMedDate not supplied

Adjuvant systemic treatment of resectable breast cancer: eleven years results of a monoinstitutional chemo-hormone-immunotherapy trial.

131 patients with resectable, node-positive breast cancer were treated at the National Institute for Cancer Research of Genoa, Italy with a systemic adjuvant regimen based on 14 cycles of chemotherapy, immunostimulation with levamisole, and--for postmenopausal patients--hormone therapy with tamoxifen. The present evaluation is performed eleven years after the admission of the first patient: so far, 75 patients (57.3%) have relapsed and 52 (39.7%) have died. An analysis of prognostic factors for relapse and death shows that the number of positive axillary lymph nodes and the dimension of the primary tumor are significantly associated with survival and relapse-free survival, while age and menopausal status are not.

Age Factors↗
PubMedDate not supplied

Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors.

Idarubicin (4-demethoxydaunorubicin) is a daunorubicin analog that has shown comparable activity and less cardiotoxicity than daunorubicin and doxorubicin in preclinical studies. Phase I and II studies appear to confirm its safety but no definitive conclusion about cardiotoxicity was possible due to the small number of patients in each study. We evaluated 77 patients with advanced solid tumors treated with oral single agent (idarubicin 15 mg/m2 for three days every 4 weeks). Physical examinations and ECGs were performed before every course of treatment and at discontinuation. Eighteen patients also received sequential radionuclide angiocardiographies for evaluation of LVEF. After the administration of a median of 135 mg/m2 of idarubicin (range 45-540), no clinical sign of cardiotoxicity was observed: in three patients minor and transient ECG changes occurred. No significant reduction in mean LVEF values was observed during treatment.

Aged↗